132 related articles for article (PubMed ID: 9654155)
1. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera.
Foa P; Massaro P; Caldiera S; LaTargia ML; Iurlo A; Clerici C; Fornier M; Bertoni F; Maiolo AT
Eur J Haematol; 1998 May; 60(5):273-7. PubMed ID: 9654155
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of recombinant interferon-alpha in polycythaemia vera.
Oztürk A; Günay A; Uskent N
Acta Haematol; 1998; 99(2):89-91. PubMed ID: 9554456
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera.
Stasi R; Brunetti M; Bussa S; Venditti A; Del Poeta G; Conforti M; Scimò MT; Cudillo L; Adorno G; Cecconi M; Amadori S; Pagano A
J Intern Med; 1997 Aug; 242(2):143-7. PubMed ID: 9279291
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data.
Taylor PC; Dolan G; Ng JP; Paul B; Collin R; Reilly JT
Br J Haematol; 1996 Jan; 92(1):55-9. PubMed ID: 8562411
[TBL] [Abstract][Full Text] [Related]
5. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa.
Finelli C; Gugliotta L; Gamberi B; Vianelli N; Visani G; Tura S
Am J Hematol; 1993 Aug; 43(4):316-8. PubMed ID: 8372816
[TBL] [Abstract][Full Text] [Related]
6. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
Gilbert HS
Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
[TBL] [Abstract][Full Text] [Related]
7. Role of interferon alpha-2a in the treatment of polycythemia vera.
Foa P; Massaro P; Ribera S; Iurlo A; Mezzanotte C; Giandalia D; Maiolo AT
Am J Hematol; 1995 Jan; 48(1):55-7. PubMed ID: 7832194
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.
Silver RT
Cancer; 2006 Aug; 107(3):451-8. PubMed ID: 16804923
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interferon alpha-2b in the treatment of polycythemia vera.
Cimino R; Rametta V; Matera C; Mele G; Mettivier V; Ferrara F
Am J Hematol; 1993 Nov; 44(3):155-7. PubMed ID: 8213763
[TBL] [Abstract][Full Text] [Related]
12. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.
Smith JW; Longo DL; Urba WJ; Clark JW; Watson T; Beveridge J; Conlon KC; Sznol M; Creekmore SP; Alvord WG
Blood; 1991 Oct; 78(7):1664-71. PubMed ID: 1912555
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone.
Massaro P; Foa P; Pomati M; LaTargia ML; Iurlo A; Clerici C; Caldiera S; Fornier M; Maiolo AT
Am J Hematol; 1997 Oct; 56(2):126-8. PubMed ID: 9326356
[TBL] [Abstract][Full Text] [Related]
14. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
[TBL] [Abstract][Full Text] [Related]
15. Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera.
Stasi R; Venditti A; Del Poeta G; Conforti M; Brunetti M; Bussa S; Amadori S; Pagano A
Am J Med Sci; 1998 Apr; 315(4):237-41. PubMed ID: 9537637
[TBL] [Abstract][Full Text] [Related]
16. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera.
Muller EW; de Wolf JT; Egger R; Wijermans PW; Huijgens PC; Halie MR; Vellenga E
Br J Haematol; 1995 Feb; 89(2):313-8. PubMed ID: 7873381
[TBL] [Abstract][Full Text] [Related]
18. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
[TBL] [Abstract][Full Text] [Related]
19. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b.
Aul C; Gattermann N; Schneider W
Eur J Haematol; 1991 Jan; 46(1):11-6. PubMed ID: 1988303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
